The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
SocinskiM.A., WeissmanC., HartL.L.. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J Clin Oncol.2006; 24(30): 4840–4847.
2.
ScagliottiG.V., KortsikC., DarkG.G.. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res.2005; 11(2, pt 1):690–696.
3.
ZinnerR.G., FossellaF.V., GladishG.W.. Phase II study of pemetrexed in combination with carboplatin in first-line treatment of advanced nonsmall cell lung cancer. Cancer.2005; 104(11): 2449–2456.
4.
SmitE.F., BurgersS.A., BiesmaB.. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol.2009; 27(12): 2038–2045.
5.
GronbergB.H., BremnesR.M., FlottenO.. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol.2009; 27(19): 3217–3224.
6.
CeresoliG.L., ZucaliP.A., FavarettoA.G.. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol.2006; 24(9): 1443–1448.
7.
CastagnetoB., BottaM., AitiniE.. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol.2008; 19(2): 370–373.
8.
SantoroA., O'BrienM.E., StahelR.A.. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol.2008; 3(7): 756–763.
9.
CarteniG., ManegoldC., GarciaG.M.. Malignant peritoneal mesothelioma – results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer.2009; 64(2): 211–218.
10.
GarinA., ManikhasA., BiakhovM.. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat.2008; 110(2): 309–315.
11.
MatulonisU.A., HorowitzN.S., CamposS.M.. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol.2008; 26(35): 5761–5766.
12.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology—Non-Small Cell Lung Cancer. V.2.2009. http://www.nccn.org. Accessed August 18, 2009.
13.
CheungY.W., CradockJ.C., VishnuvajjalaB.R., FloraK.P.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987; 44(1): 124–130.
14.
GrunbergS.M., OsobaD., HeskethP.. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer.2005; 13(2): 80–84.
15.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines—Antiemesis. V.3.2009. http://www.nccn.org. Accessed August 20, 2009.
16.
KrisM.G., HeskethP.J., SomerfieldM.R..; American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
17.
Multinational Association for Supportive Care in Cancer.Antiemetic Guidelines—March 2008 Update.http://www.mascc.org. Accessed August 20, 2009.
18.
GelingO., EichlerH.G.Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
19.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
20.
Alimta [package insert].Indianapolis, IN: Eli Lilly and Company; 2009.
21.
MarkmanM., KennedyA., WebsterK.. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol.1999: 17(4): 1141–1145.
22.
HesterbergP.E., BanerjiA., OrenE.. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol.2009; 123(6): 1262–1267.
23.
LeeC.W., MatulonisU.A., CastellsM.C.Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol.2005; 99(2): 393–399.
24.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
25.
National Comprehensive Cancer Network.NCCN Clinical Practice Guide lines in Oncology—Myeloid Growth Factors. V.1.2009. http://www.nccn.org. Accessed August 21, 2009.
26.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
27.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–402.
28.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastics extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
29.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
30.
WaddellJ.A., SolimandoD.A.Verifying carboplatin dose calculations in adult patients with the Calvert and modified Calvert formulas. Hosp Pharm.2000; 35(9): 914–922.
31.
FloydJ., MirzaI., Sachs, PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
